文献速递乳腺癌

新辅助化疗后长期预后风险与残留肿瘤负荷及乳腺癌亚型相关

Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
PubMed 文献 · J Clin Oncol · 2017-01-30

本研究在五个队列中评估新辅助化疗后残留肿瘤负荷(RCB)指数对长期预后的预测价值。连续RCB指数在各表型亚组内均具预后意义,RCB分级可分层预后风险,且在各表型亚组和yp分期类别内均有效。作者指出其机构研究结果需外部验证。

要点

  • 连续RCB指数在各表型亚组内均具预后意义,独立于其他临床病理变量。
  • RCB分级可整体、各表型亚组内及yp分期类别内分层预后风险。
  • 三阴性乳腺癌10年无复发生存率:pCR 86%、RCB-I 81%、RCB-II 55%、RCB-III 23%。

核心结论

  • RCB对全部三种表型亚组乳腺癌患者新辅助化疗后的长期生存均具预后意义。
  • 作者的机构研究结果应进行外部验证。

研究设计与样本

  • 病理审阅测量连续RCB指数(pCR为RCB=0;残留病变分为RCB-I、RCB-II、RCB-III三级)及残留病变yp分期。
  • 患者接受前瞻性生存观察。
  • 三个患者队列接受紫杉醇(T)后序贯氟尿嘧啶、多柔比星和环磷酰胺(T/FAC):原始开发队列(T/FAC-1)、验证队列(T/FAC-2)和独立验证队列(T/FAC-3)。
  • 另一个验证队列仅接受FAC化疗;第五个队列接受曲妥珠单抗(H)同步联合序贯紫杉醇和氟尿嘧啶、表柔比星、环磷酰胺(FEC;H+T/FEC)。
  • 表型亚组由诊断时激素受体(HR)和HER2状态定义,分类为HR阳性/HER2阴性、HER2阳性(HR阴性/HER2阳性或HR阳性/HER2阳性)或三受体阴性。

主要发现

  • 五个队列(T/FAC-1 [n=219]、T/FAC-2 [n=262]、T/FAC-3 [n=342]、FAC [n=132]和H+T/FEC [n=203])的中位无事件随访时间分别为13.5、9.1、6.8、16.4和7.1年。
  • 连续RCB指数在各表型亚组内均具预后意义,独立于其他临床病理变量。
  • RCB分级可整体、各表型亚组内及yp分期类别内分层预后风险。
  • 三阴性乳腺癌四个RCB分级(pCR、RCB-I、RCB-II和RCB-III)的10年无复发生存率估计分别为86%、81%、55%和23%。
  • 合并T/FAC队列中HR阳性/HER2阴性乳腺癌四个RCB分级(pCR、RCB-I、RCB-II和RCB-III)的10年无复发生存率估计分别为83%、97%、74%和52%;H+T/FEC队列中分别为95%、77%、47%和21%。

关键数值与推荐

  • 连续RCB指数在各表型亚组内均具预后意义,独立于其他临床病理变量。
  • RCB分级可整体、各表型亚组内及yp分期类别内分层预后风险。
  • 三阴性乳腺癌10年无复发生存率:pCR 86%、RCB-I 81%、RCB-II 55%、RCB-III 23%。
  • 合并T/FAC队列HR阳性/HER2阴性乳腺癌10年无复发生存率:pCR 83%、RCB-I 97%、RCB-II 74%、RCB-III 52%。
  • H+T/FEC队列10年无复发生存率:pCR 95%、RCB-I 77%、RCB-II 47%、RCB-III 21%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者的机构研究结果应进行外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose To determine the long-term prognosis in each phenotypic subset of breast cancer related to residual cancer burden (RCB) after neoadjuvant chemotherapy alone, or with concurrent human epidermal growth factor receptor 2 (HER2)-targeted treatment. Methods We conducted a pathologic review to measure the continuous RCB index (wherein pathologic complete response has RCB = 0; residual disease is categorized into three predefined classes of RCB index [RCB-I, RCB-II, and RCB-III]), and yp-stage of residual disease. Patients were prospectively observed for survival. Three patient cohorts received paclitaxel (T) followed by fluorouracil, doxorubicin, and cyclophosphamide (T/FAC): original development cohort (T/FAC-1), validation cohort (T/FAC-2), and independent validation cohort (T/FAC-3). Another validation cohort received FAC chemotherapy only, and a fifth cohort received concurrent trastuzumab (H) with sequential paclitaxel and fluorouracil, epirubicin, and cyclophosphamide (FEC; H+T/FEC). Phenotypic subsets were defined by hormone receptor (HR) and HER2 status at diagnosis, classified as HR-positive/HER2-negative, HER2-positive (HR-negative/HER2-positive or HR-positive/HER2-positive), or triple receptor-negative. Relapse-free survival estimates were determined from Kaplan-Meier analysis and compared using the log-rank test. Results Five cohorts (T/FAC-1 [n = 219], T/FAC-2 [n = 262], T/FAC-3 [n = 342], FAC [n = 132], and H+T/FEC [n = 203]) had median event-free follow-up of 13.5, 9.1, 6.8, 16.4, and 7.1 years, respectively. Continuous RCB index was prognostic within each phenotypic subset, independent of other clinical-pathologic variables. RCB classes stratified prognostic risk overall, within each phenotypic subset, and within yp-stage categories. Estimates of 10-year relapse-free survival rates in the four RCB classes (pathologic complete response, RCB-I, RCB-II, and RCB-III) were 86%, 81%, 55%, and 23% for triple receptor-negative; 83%, 97%, 74%, and 52% for HR-positive/HER2-negative in the combined T/FAC cohorts; and 95%, 77%, 47%, and 21% in the H+T/FEC cohort. Conclusion RCB was prognostic for long-term survival after neoadjuvant chemotherapy in all three phenotypic subsets of breast cancer. Our institutional findings should be externally validated.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Symmans WF, Wei C, Gould R, et al. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. J Clin Oncol. 2017. PMID: 28135148. doi:10.1200/JCO.2015.63.1010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。